Cavitation Technologies, Inc.
0.0700+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · CVAT · USD
Key Stats
Market Cap
20.24MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-K
FY2025 results
Cavitation Technologies posted FY2025 revenue of $203,000, down 85% year-over-year from $1.36 million, driven by sharply reduced Nano Reactor sales to Desmet before the October 2024 patent assignment that fetched an $880,000 gain. This one-time boost turned an operating loss of $987,000 into a slim net loss of $113,000, while cash climbed to $249,000 amid $806,000 in operating outflows. No quarterly breakdowns emerged, but trials in Permian Basin water remediation and Canadian agriculture hint at Q1 FY2026 momentum, with Hydro-Plasma tech testing underway. The firm settled related-party debts via stock and warrants, preserving liquidity without dividends or buybacks. No annual guidance surfaced, yet revenue from new ventures could accelerate. Cybersecurity threats loom, risking IP and operations.
10-Q
Q3 FY2025 results
Cavitation Technologies posted Q3 FY2025 revenue of $122,000, down 76.5% y/y from $519,000, reflecting the October 2024 patent assignment to Desmet that curbed Nano Reactor sales; nine-month revenue fell 72.2% y/y to $198,000, yet a $880,000 gain on the assignment flipped operations loss of $753,000 into net income of $122,000, up 90.6% y/y. Gross margin held at 79.5% for the quarter, while operating expenses climbed 81.6% y/y to $325,000, driven by $90,000 in stock-based compensation and higher R&D. Cash swelled to $432,000 on the deal's proceeds, with $624,000 used in operations; total debt stands at $136,000 under the EIDL note at 3.75%. The patent deal secured a royalty-free license for water treatment and beverage applications, fueling pilots in the Permian Basin and agriculture. Patent sales to Desmet unlocked fresh paths.
10-Q
Q2 FY2025 results
Cavitation Technologies swung to a net income of $579,000 for Q2 FY2025 ended December 31, 2024, from a $16,000 loss a year earlier, driven by an $880,000 gain on patent assignment to Desmet that offset a 60.4% y/y revenue drop to $76,000 from Nano Reactor sales. Gross margin held steady at 82.9%, yet operating loss widened to $299,000 from $14,000 due to higher G&A expenses, including $105,000 in warrant compensation. The patent deal, closed October 9, 2024, for $880,000 cash, assigned vegetable oil patents while reserving exclusive rights for water/wastewater and alcoholic beverage applications. Cash climbed to $681,000, with $128,000 long-term EIDL debt at 3.75%; free cash flow not disclosed in the 10-Q. EPS reconciles at $0.00 with 284.3 million diluted shares. Patent assignment unlocked fresh paths. Regulatory hurdles in water treatment markets loom large.
10-Q
Q1 FY2025 results
Cavitation Technologies posted a narrower Q1 FY2025 operating loss of $226,000, down 9.6% y/y from $250,000, as general and administrative expenses ticked up slightly to $218,000 while R&D costs plunged 77.8% to $8,000 on slower project progress. No revenue materialized in the quarter, leaving net loss at $227,000 versus $251,000 last year, with the gap to operating loss negligible at just $1,000 in interest. Cash dwindled to $2,000 by quarter-end after $175,000 used in operations, but a timely $880,000 patent assignment to Desmet—retaining exclusive rights in water treatment and beverages—bolstered liquidity. Debt stands at $137,000 under the EIDL note at 3.75% over 30 years. Yet going-concern doubts linger amid the $27M accumulated deficit. Trials in Permian water remediation and agriculture hint at revenue by mid-2025. Cash is perilously low.
10-K
FY2024 results
Cavitation Technologies swung to a $439,000 net profit for FY2024 ended June 30, 2024, up from a $2.04 million loss the prior year, fueled by revenue surging 230% to $1.363 million—driven by $865,000 in Nano Reactor sales to Desmet (up from $413,000) and a one-time $498,000 license fee from their renewed agreement. While quarterly breakdowns aren't detailed, the full-year momentum reflects Desmet's steady monthly advances of $972,000, applied against sales, with no revenue from water treatment or beverage ventures. Cash climbed to $179,000, generating $172,000 from operations amid slashed G&A expenses, yet a $403,000 working capital deficit persists. No dividends or buybacks; capex stayed minimal. Desmet could terminate if sales lag below six systems annually. Oil price volatility threatens adoption in frac water markets.
IPO
Website
Employees
Sector
Industry
CETY
Clean Energy Technologies, Inc.
2.52+0.05
CGEH
Capstone Green Energy Holdings
2.57-0.13
CHMX
Next-ChemX Corporation
5.40+0.00
CLEV
Concrete Leveling Systems Inc.
0.67-0.02
CVV
CVD Equipment Corporation
4.16-0.04
ITT
ITT Inc.
195.47+19.58
NDSN
Nordson Corporation
233.18-2.14
NEWH
NewHydrogen Inc.
0.03+0.00
NNE
Nano Nuclear Energy Inc.
47.83+3.69
WTS
Watts Water Technologies, Inc.
273.15-2.33